Potential Mechanisms for Cancer Resistance in Elephants and Comparative Cellular Response to DNA Damage in Humans

Area of Science:

• Evolutionary Medicine
• Comparative Oncology
• Genomics

Background:

• Evolutionary medicine offers insights into human physiology and disease, including cancer biology.
• Elephants, despite their size and longevity, show resistance to cancer, prompting investigation into their unique cellular mechanisms.

Purpose of the Study:

• To identify cancer resistance mechanisms in elephants.
• To compare cellular responses to DNA damage in elephants, healthy humans, and Li-Fraumeni syndrome (LFS) patients.

Main Methods:

• Analyzed necropsy data from 36 mammalian species, including 644 elephants, to assess cancer resistance.
• Sequenced African and Asian elephant genomes to identify cancer resistance-related genes.
• Exposed peripheral blood lymphocytes from elephants, human controls, and LFS patients to ionizing radiation and doxorubicin to compare DNA damage response and apoptosis.

Main Results:

• Cancer mortality did not correlate with body size or lifespan across mammals; elephants showed lower cancer mortality (4.81%) than humans (11%-25%).
• African elephants possess at least 20 copies of the TP53 gene, unlike humans with 2 copies.
• Elephant lymphocytes exhibited significantly higher rates of p53-mediated apoptosis following DNA damage compared to human lymphocytes.

Conclusions:

• Elephants' lower cancer rates may be linked to their multiple TP53 gene copies.
• Enhanced apoptotic response in elephant cells following DNA damage suggests a potent cancer suppression mechanism.
• These findings may pave the way for evolutionary-based strategies in cancer suppression research.